BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34027681)

  • 21. A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy.
    Pal RP; Ahmad R; Trecartan S; Voss J; Ahmed S; Bazo A; Lloyd J; Walton TJ
    J Urol; 2018 Aug; 200(2):302-308. PubMed ID: 29477717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
    Pepe P; Garufi A; Priolo G; Pennisi M
    Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incidence of hyperechoic prostate cancer in transrectal ultrasound-guided biopsy specimens.
    Spajic B; Eupic H; Tomas D; Stimac G; Kruslin B; Kraus O
    Urology; 2007 Oct; 70(4):734-7. PubMed ID: 17991546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer.
    Tan N; Lin WC; Khoshnoodi P; Asvadi NH; Yoshida J; Margolis DJ; Lu DS; Wu H; Sung KH; Lu DY; Huang J; Raman SS
    Radiology; 2017 Apr; 283(1):130-139. PubMed ID: 27861110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies.
    Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Preisser F; Tilki D; Fisch M; Graefen M; Budäus L
    J Urol; 2018 Nov; 200(5):1035-1040. PubMed ID: 29935274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?
    Delongchamps NB; Lefèvre A; Bouazza N; Beuvon F; Legman P; Cornud F
    J Urol; 2015 Apr; 193(4):1198-204. PubMed ID: 25451824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
    Roethke MC; Kuru TH; Schultze S; Tichy D; Kopp-Schneider A; Fenchel M; Schlemmer HP; Hadaschik BA
    Eur Radiol; 2014 Feb; 24(2):344-52. PubMed ID: 24196383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How Often is the Dynamic Contrast Enhanced Score Needed in PI-RADS Version 2?
    Roh AT; Fan RE; Sonn GA; Vasanawala SS; Ghanouni P; Loening AM
    Curr Probl Diagn Radiol; 2020; 49(3):173-176. PubMed ID: 31126664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer: diagnostic yield of modified transrectal ultrasound-guided twelve-core combined biopsy (targeted plus systematic biopsies) using prebiopsy magnetic resonance imaging.
    Song C; Park SY
    Abdom Radiol (NY); 2021 Oct; 46(10):4974-4983. PubMed ID: 34181040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apparent diffusion coefficient values are superior to transrectal ultrasound-guided prostate biopsy for the assessment of prostate cancer aggressiveness.
    Li C; Chen M; Wang J; Wang X; Zhang W; Zhang C
    Acta Radiol; 2017 Feb; 58(2):232-239. PubMed ID: 27055916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of mandated prospectively reported apparent diffusion coefficient values on the rates of positivity for clinically significant prostate cancer by PI-RADS score.
    Shaish H; Casals R; Ahmed F; Makkar J; Wenske S
    Acta Radiol; 2021 Jan; 62(1):139-144. PubMed ID: 32312102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score.
    Osses DF; van Asten JJ; Kieft GJ; Tijsterman JD
    World J Urol; 2017 Feb; 35(2):207-212. PubMed ID: 27287889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score.
    Porpiglia F; DE Luca S; Passera R; Manfredi M; Mele F; Bollito E; DE Pascale A; Cossu M; Aimar R; Veltri A
    Anticancer Res; 2016 Sep; 36(9):4833-9. PubMed ID: 27630337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing the Number of Cores Targeted During Prostate Magnetic Resonance Imaging Fusion Target Biopsy.
    Kenigsberg AP; Renson A; Rosenkrantz AB; Huang R; Wysock JS; Taneja SS; Bjurlin MA
    Eur Urol Oncol; 2018 Oct; 1(5):418-425. PubMed ID: 31158081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of complications rates between multiparametric magnetic resonance imaging-transrectal ultrasound (TRUS) fusion and systematic TRUS prostatic biopsies.
    Queiroz MRG; Falsarella PM; Mariotti GC; Lemos GC; Baroni RH; Mussi TC; Garcia RG
    Abdom Radiol (NY); 2019 Feb; 44(2):732-738. PubMed ID: 30255444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
    Urol Int; 2017; 99(4):384-391. PubMed ID: 28651247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-Stop MRI and MRI/transrectal ultrasound fusion-guided biopsy: an expedited pathway for prostate cancer diagnosis.
    Tafuri A; Ashrafi AN; Palmer S; Shakir A; Cacciamani GE; Iwata A; Iwata T; Cai J; Sali A; Gupta C; Medina LG; Stern MC; Duddalwar V; Aron M; Gill IS; Abreu A
    World J Urol; 2020 Apr; 38(4):949-956. PubMed ID: 31175460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.